España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Ultragenyx Pharmaceutical
RARE
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Ultragenyx Pharmaceutical (RARE) Forecast
News
Earnings
Ultragenyx Pharmaceutical (RARE) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock
Ultragenyx Pharmaceutical Stock (NASDAQ: RARE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, November 12, 2024
Canaccord Genuity Maintains Buy on Ultragenyx...
Benzinga Newsdesk
Monday, November 11, 2024
Saturday, Ultragenyx Pharmaceutical Announced...
Benzinga Newsdesk
Wednesday, November 06, 2024
Canaccord Genuity Maintains Buy on Ultragenyx...
Benzinga Newsdesk
RBC Capital Reiterates Outperform on Ultragen...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on Ul...
Benzinga Newsdesk
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Ultragen...
Benzinga Newsdesk
Tuesday, November 05, 2024
Ultragenyx Pharmaceutical Sees FY24 Revenue $...
Benzinga Newsdesk
Ultragenyx Pharmaceutical Q3 2024 GAAP EPS $(...
Benzinga Newsdesk
Monday, November 04, 2024
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
Benzinga Insights
Tuesday, October 22, 2024
Cantor Fitzgerald Reiterates Overweight on Ul...
Benzinga Newsdesk
Monday, October 21, 2024
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical
Benzinga Insights
TD Cowen Maintains Buy on Ultragenyx Pharmace...
Benzinga Newsdesk
Monday, October 07, 2024
Ultragenyx Receives FDA Breakthrough Therapy ...
Benzinga Newsdesk
Thursday, October 03, 2024
Ultragenyx Provides Update on Stage 1 Cohorts...
Benzinga Newsdesk
Tuesday, October 01, 2024
Cantor Fitzgerald Reiterates Overweight on Ul...
Benzinga Newsdesk
Thursday, September 26, 2024
RBC Capital Reiterates Outperform on Ultragen...
Benzinga Newsdesk
Friday, September 20, 2024
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ul...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Overweight on Ul...
Benzinga Newsdesk
Tuesday, August 06, 2024
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Vandana Singh
Monday, August 05, 2024
Barclays Maintains Overweight on Ultragenyx P...
Benzinga Newsdesk
Friday, August 02, 2024
Goldman Sachs Maintains Buy on Ultragenyx Pha...
Benzinga Newsdesk
Ultragenyx Pharmaceuticals shares are trading...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Ult...
Benzinga Newsdesk
Wedbush Maintains Neutral on Ultragenyx Pharm...
Benzinga Newsdesk
Thursday, August 01, 2024
Ultragenyx Pharmaceuticals shares are trading...
Benzinga Newsdesk
Ultragenyx Pharmaceutical Raises FY24 Revenue...
Benzinga Newsdesk
Ultragenyx Pharmaceutical Q2 EPS $(1.52) Beat...
Benzinga Newsdesk
Wednesday, July 24, 2024
Ultragenyx To Present GTX-102 Angelman Syndro...
Benzinga Newsdesk
Tuesday, July 23, 2024
Canaccord Genuity Maintains Buy on Ultragenyx...
Benzinga Newsdesk
Monday, July 22, 2024
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Vandana Singh
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ul...
Benzinga Newsdesk
Thursday, July 18, 2024
Wedbush Reiterates Neutral on Ultragenyx Phar...
Benzinga Newsdesk
Wednesday, July 17, 2024
Ultragenyx Aligns With FDA On Phase 3 Study E...
Benzinga Newsdesk
Thursday, June 27, 2024
'Biogen Is Pursuing More Dealmaking This Year...
Benzinga Newsdesk
Friday, June 14, 2024
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
Ultragenyx Pharmaceutical shares are trading ...
Benzinga Newsdesk
Reported Earlier, Ultragenyx Prices $350M Pub...
Benzinga Newsdesk
Thursday, June 13, 2024
Ultragenyx Posts New Data From Bone Disease Study
Zacks
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
Wednesday, June 12, 2024
Ultragenyx shares are trading lower after the...
Benzinga Newsdesk
Ultragenyx Pharmaceutical Commences $350M Pub...
Benzinga Newsdesk
Ultragenyx Plans To File For Accelerated Appr...
Benzinga Newsdesk
Ultragenyx Pharmaceuticals shares are trading...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on Ul...
Benzinga Newsdesk
Tuesday, June 11, 2024
Ultragenyx, Mereo Report 14-Month Results Fro...
Benzinga Newsdesk
Thursday, June 06, 2024
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Avi Kapoor
Goldman Sachs Upgrades Ultragenyx Pharmaceuti...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
